Dermata Therapeutics, Inc. (DRMA) Form 10-Q — Aug 11, 2026
Dermata Therapeutics disclosed substantial doubt about its ability to continue as a going concern in its Q2 2026 10-Q, with cash of $4.4 million as of June 30, 2026 expected to fund operations only into the fourth quarter of 2026. Management stated the doubt is not alleviated by its plans, and the ATM equity program has no remaining capacity. The company reported a Q2 net loss of $3.0 million, widened from $1.7 million a year ago, as SG&A more than doubled to $2.8 million on pre-launch commercialization spending and roughly $0.7 million of higher legal fees tied to litigation with former licensor Villani, Inc.
Key figures
- Total Assets
- 5320799
- Cash Position
- 4412764
- Shares Outstanding
- 4022143
- Cash runway
- into the fourth quarter of 2026
- Total liabilities
- 1833079
- Rd expense 6m 2026
- 596287
- Accumulated deficit
- 78048665
- Sga expense 6m 2026
- 4343662
- Stockholders equity
- 3487720
- Warrants outstanding
- 5424598
- Six month 2025 net loss
- -4004680
- Reverse split ratio 2025
- 1-for-10
- January 2026 atm net proceeds
- 1994051
- Market value listed securities
- below $5 million
- Price per weekly treatment usd
- 45
- Cash used in operations 6m 2026
- 4901246
- Potentially dilutive securities
- 5589009
- December 2025 pipe gross proceeds
- 4100000
- Foundational treatment retail price usd
- 178
Price after filing
Close on the filing date to close N calendar days later (from $1.12). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.